Brussels - September 14, 2001Analysts and Investors Meeting
« A FUNDAMENTAL« A FUNDAMENTAL
STRATEGIC CHANGESTRATEGIC CHANGE
FOR SOLVAY »FOR SOLVAY »
PHARMACEUTICALSPHARMACEUTICALS
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 2/08.092Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
VALUE CREATING IN
PHARMACEUTICALS
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 3/08.093Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
SOLVAY PHARMACEUTICALSSOLVAY PHARMACEUTICALSOUR VISIONOUR VISION
““Our aim is to find, produce and deliver Our aim is to find, produce and deliver
pharmaceutical products to help pharmaceutical products to help
physicians to treat diseases physicians to treat diseases
in our 4 therapeutic areas and improve in our 4 therapeutic areas and improve
the quality of life for patients” the quality of life for patients”
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 4/08.094Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
SOLVAY PHARMACEUTICALSSOLVAY PHARMACEUTICALSmidsize company thrives by focusing on specialty areasmidsize company thrives by focusing on specialty areas
““The giants’ disdain for small drugsThe giants’ disdain for small drugscould work to the advantage ofcould work to the advantage of
midsize pharmaceutical companies”midsize pharmaceutical companies”McKinsey, 2001McKinsey, 2001
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 5/08.095Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PHARMACEUTICALS SECTORPHARMACEUTICALS SECTORTargets by 2005+
Sales > EUR 2.5 Bn from 2005 onwardSales > EUR 2.5 Bn from 2005 onward
EBIT/sales margin > 15% EBIT/sales margin > 15%
ROI > 20%ROI > 20%
North American sales at 50% of total salesNorth American sales at 50% of total sales
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 6/08.096Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PHARMACEUTICALS SECTORPHARMACEUTICALS SECTORTargets by 2005+
922
1548
2500
0
500
1000
1500
2000
2500
1996 2000 2005+
15%/y15%/y(+23% in US)(+23% in US)
World+ 10%/y required + 10%/y required
to achieve to achieve EUR 2.5 BnEUR 2.5 Bn
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 7/08.097Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
Growth of existing drugsGrowth of existing drugs Recent launch of new drugsRecent launch of new drugs Contribution of molecules under Contribution of molecules under
developmentdevelopment
PHARMACEUTICALS : FINANCIAL OBJECTIVE by 2005 sales of EUR 2.5 Bnsales of EUR 2.5 Bn EBIT/sales margin of 15%EBIT/sales margin of 15%
Strengthened by alliances and partnerships
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 8/08.098Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
« Expansion of global commercial platform »
J. Wessolowski, Head of Pharmaceuticals Marketing & Operations
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 9/08.099Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PHARMACEUTICALS WORLDWIDE PRESENCEPHARMACEUTICALS WORLDWIDE PRESENCE
Total 2000 sales : EUR 1,548 M
Tokyo (Japan)
Brussels (B)Hannover (D)Weesp (NL)
Atlanta (USA)
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 10/08.0910Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
STRONG WORLDWIDE MARKET POSITIONSTRONG WORLDWIDE MARKET POSITION
Europe US World Solvay (11)
WorldwideMarketShare
Digestives/Enzymes 1 2 1 33%Laxatives 1 - 3 6%Irritable Bowel Syndrome 1 - 1 28%Hormone Replacement Therapy
female 5 2 2 9%male (*) - 1 1 22%
Antidepressants + OCD 13 8 9 2%Vertigo (Ménière’s disease) 1 - 1 39%* only sold in the USIMS data
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 11/08.0911Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
STRONG GROWTH IN 4 THERAPEUTIC AREASSTRONG GROWTH IN 4 THERAPEUTIC AREAS
HRT* PRODUCTS 470 + 21 % Estratest® 145+ 17% Duphaston® 56+ 7% Prometrium® 49+ 93% AndroGel® (**) 29n.a. Femoston® 19+ 60%
GASTROENTEROLOGY 473 + 11 % Creon® 119 + 6% Duphalac® 810 Duspatal® 59+ 2% Pantoloc® 54+ 101% Rowasa® 47+ 8% Dicetel® 34 + 9%
PSYCHIATRY 419 + 13 % Luvox® 271 + 19% Serc® 72 + 2%
CARDIOLOGY 106 + 6 % Physiotens® 39+ 26% Teveten® 16+ 20%
(*) Hormone Replacement Therapy (**) marketed since June 2000
Therapeutic fields/ Sales in 2000 2000/1999Products (M EUR) (%)
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 12/08.0912Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
+ 19% SALES in H1/01 (+34% in the US)+ 19% SALES in H1/01 (+34% in the US)
HRT 267 + 46%
GASTRO 247 + 12%
CARDIO 73 + 47%
PSY 181 - 10%
H1/01 vs H1/00
• Estratest® 89 + 62%• AndroGel® 51 n.s.• Prometrium® 31 + 45%• (Cenestin (Duramed) 15 + 112%)
• Creon® 65 + 10%• Pantoloc® 37 + 65%• Rowasa® 27 + 29%• Dicetel® 20 + 21%
• Physiotens® 23 + 20%• Teveten® 17 + 157%• Aceon® 9 (*)
• Luvox® (world) 86 - 28% US down Japan up
• Marinol® 24 + 178%
Success of recently launched drugsSuccess of recently launched drugs
M EUR
H1/01H1/01M EUR M EUR vs H1/00vs H1/00
(*) Aceon® sales were negligible in H1/00
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 13/08.0913Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
1999 2000 2001
Line extension: First launch of Femoston (conti.) in UK and Switzerland
Launch of Femoston (conti.) in Germany, further launches to follow
Poland, South Africa, Norway, Hungary, Sweden, Belgium, Russian Fed.
Lithuania, Croatia, Czech Rep., Slovak Rep., Malta, Bulgaria
Lebanon, Jordan, Saudi Arabia, Kuwait, U.A.E., Romania, Ukraine
First launch of Teveten (in Germany and US followed by further launches through the world
The Netherlands, Austria, UK, Ire, Switzerland, Australia, Poland, Italy, France, Russian Fed.
Fin, Gr, Canada, Sweden, Denmark, Norway, Spain, Belgium
First SSRI launched in Ja-pan; marketed by Fujisawa and Meiji Seika for depression and OCD
MAJOR RECENT PRODUCT LAUNCHES (1)MAJOR RECENT PRODUCT LAUNCHES (1)
Femoston®
Physiotens®
Teveten®
Luvox®
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 14/08.0914Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
USA
Aceon ®
Androgel ®(marketing agreement with TAP
since June 2001)
Cenestin ®(with Duramed Inc.)
MAJOR RECENT PRODUCT LAUNCHES (2)MAJOR RECENT PRODUCT LAUNCHES (2)
2000 2001
Launch of Teveten
Marinol ®(100% Solvay)
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 15/08.0915Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
2001 2003 2004 2005 2006
Teveten + HCT, Europe and U.S.
Presomen Conti,
(Germany only)
Moxonidine + HCT (Europe)
Luvox CR
Creon (Japan)
Estrogel US
cilansetron,Europe and U.S.
Tedisamil IV
CombigelE + P-gel
Influvac-Intranasal
SLV 306
DU 127090
Tedisamil PO
FUTURE PRODUCT LAUNCHESFUTURE PRODUCT LAUNCHES
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 16/08.0916Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
GEOGRAPHICAL EXPANSIONGEOGRAPHICAL EXPANSION
76%
24%
60%
40%50% 50%
0%
10%
20%
30%
40%
50%
60%
70%
80%
ROW NAFTA1996
In %
of
tota
l p
har
ma
sale
s
2005+ROW = Rest of the World
targettarget : 50/50 balance between NAFTA / Rest of the world : 50/50 balance between NAFTA / Rest of the world
ROW NAFTA ROW NAFTA2000
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 17/08.0917Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
GEOGRAPHIC GROWTH OBJECTIVESGEOGRAPHIC GROWTH OBJECTIVES
To increase global market share up to 0.8 - 1 % of the world market
(Market share currently 0.5%)
To get 1% in countries where Solvay has a presence
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 18/08.0918Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
Countries in Billion USDSolvay
market share
* USA Market Estimates include audited US Mail Order data, **data for the Netherlands is based on estimated sales only (IMS data)
THE WORLDWIDE MARKETTHE WORLDWIDE MARKETRank
% of worldwidemarket
1 USA* 149.8 41.3% <1%2 Japan 57.8 15.9% <1%3 Germany 17.3 4.8% >1%4 France 16.8 4.6% >1%
6 Italy 11.0 3.0% <1%5 UK 11.1 3.0% <1%
10 Spain 6.2 1.7% >1%
8 Brazil 6.7 1.8% <1%7 China 6.8 1.9% <1%
9 Canada 6.3 1.7% <1%
11 Mexico 6.0 1.7% not present12 Argentina 3.7 1.0% not present13 South Korea 3.7 1.0% not present14 India 3.6 1.0% <1%15 Australia 3.1 0.9% <1%16 Turkey 3.1 0.9% not present
19 Belgium 2.5 0.7% >1%
17 Netherlands ** 2.6 0.7% <1%18 Poland 2.5 0.7% <1%
20 Taiwan 2.5 0.7% not present
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 19/08.0919Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
ACQUISITIONS ACQUISITIONS NEW PRODUCTS/NEW COMPANIESNEW PRODUCTS/NEW COMPANIES
Recent/Short termRecent/Short term Medium term Medium term Long termLong term0 - 2 years0 - 2 years > 2 - < 5 years > 2 - < 5 years > 5 - years> 5 - years
USA Unimed X X
EUROPEItaly XUK XPoland (X)
+ Continuous growth Central/Eastern Europe, especially Russia+ geographical expansion in Turkey
AMERICASBrazil SintofarmaArgentina XMexico XCanada XASIAJapan X
+ geographical expansion in India
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 20/08.0920Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
USAUSA Androgel®Androgel® :: with TAP Phamaceutical Cowith TAP Phamaceutical Co Cenestin®Cenestin® :: with Duramedwith Duramed Remeron® sol-tabRemeron® sol-tab :: with Organonwith Organon
CANADACANADA Pantoloc® Pantoloc® :: with Byk-Guldenwith Byk-Gulden Teveten ®Teveten ® :: with Fournierwith Fournier
SOUTH AMERICASOUTH AMERICA Mexico Mexico :: with Byk Guldenwith Byk Gulden ArgentinaArgentina :: with Byk Guldenwith Byk Gulden
EUROPEEUROPE GermanyGermany :: with Aventis for Teveten®with Aventis for Teveten® Spain Spain :: with Roche for Cilazapril®with Roche for Cilazapril® ItalyItaly :: with Upjohn for Frontal®with Upjohn for Frontal®
with Almirall/Prodesfarma for Dumirox® /Almotrex®with Almirall/Prodesfarma for Dumirox® /Almotrex®
ASIAASIA Japan Japan :: with Meiji and Fujisawa for Luvox®with Meiji and Fujisawa for Luvox® Japan Japan :: with Amano and with Meiji for Creon® with Amano and with Meiji for Creon® (under negotiation)(under negotiation) ChinaChina :: with Hexal (hostpartnership)with Hexal (hostpartnership)
ALLIANCES WITH SOUND PARTNERSALLIANCES WITH SOUND PARTNERSIN CO-PROMOTION/LICENSESIN CO-PROMOTION/LICENSES
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 21/08.0921Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
EXPANSION OF COMMERCIAL SALES FORCEEXPANSION OF COMMERCIAL SALES FORCEAbout 5,300 sales representatives worldwide (versus 2,900 in 1998)
including sales force partners or third parties
SOLVAY SALES FORCE 3,800 United States 1,000 twofold increase between 98 and 2000
establishment of a primary care network acquisition of Unimed Pharmaceuticals Inc + alliance with Duramed (female HRT) and TAP (male
HRT, Androgel)) Brazil 180 Acquisition of Sintofarma in Brazil Canada 64 Western Europe 1,355 Central/Eastern Europe 300 Asia/Middle East 907
THIRD PARTIESJapan1,500 distribution agreement with Fujisawa/Meiji Seika
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 22/08.0922Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
DOUBLE DIGIT GROWTHDOUBLE DIGIT GROWTH
96 97 98 99 00 H1/01
over the last 5 years
Sales 922 1,049 1,167 1,349 1,548 830
Sales Growth (yoy) +15% +14% +11% +16% +15% +19%
EBIT 97 118 135 157 134* 59
EBIT growth (yoy) +38% +22% +14% +16% -15%* +157%
EBIT/SALES 10% 11% 12% 12% 9%* 7%**
* due to voluntary marketing investments for the launch of 5 new drugs** with H1 lower than H2 due to seasonal effect
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 23/08.0923Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
« Pharmaceuticals R&Dfor tomorrow ’s success »
W. Cautreels, Worldwide Head ofR&D Pharmaceuticals
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 24/08.0924Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
Promising Development ProjectsPromising Development Projects an update by therapeutic area
But First An Update on Actions But First An Update on Actions Announced EarlierAnnounced Earlier
towards optimal decision making, output and effectiveness in R&D
strategic partnerships for biotech, special skills and value optimization
CONTENT OF PRESENTATIONCONTENT OF PRESENTATION
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 25/08.0925Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
R&D EFFECTIVENESS IMPROVEMENTSR&D EFFECTIVENESS IMPROVEMENTS
handle the improved output from biotechnology based discovery programs:more compounds in development New biotech platform implemented New biotech platform implemented
accelerate the development process by working more effectively with expert Clinical Research Organisations as partners:reduce « time to market » Quintiles agreement implemented Quintiles agreement implemented
concentrate one function on one site:improve efficiency by avoiding duplications Implementation started Implementation started
shift internal R&D costs to external costs towards 50/50:increased portfolio development spending Implementation started Implementation started
(e.g. cilansetron)(e.g. cilansetron)
R&D EFFORTS BETTER FOCUSED (not reduced)R&D EFFORTS BETTER FOCUSED (not reduced)
Weesp Weesp (Nl),(Nl), Hannover Hannover (D),(D), Marietta and Chicago Marietta and Chicago (US),(US), Tokyo Tokyo (J)(J)
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 26/08.0926Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
ProgramsProgramsDDProof ofPrincipleProof ofPrinciple ProjectsProjects LL ProductsProducts
Discovery and Biotech• for Compounds (Arqule +
Evotec + Syncom)• for Screening Technologies
(Euroscreen + Cerep)• for Targets (Innogenetics +
Euroscreen)
Development • in psychosis: Lundbeck• in HRT: several projects, E/P
gel with Antares• Lipase with Meristem• Intranasal influenza vaccine
with West
In preparation: preferred partner• for execution of clinical trials• with established quality global network• and state-of-the-art IT systems
QUINTILES
Business• Fujisawa/Meiji Seika (Jp)for
LUVOX & DEPROMEL• Byk-Gulden (D):
PANTOLOC in Canada• Several companies for
TEVETEN co-marketing• ANDROGEL co-marketing
with TAP in the US
Strategic Partnering makes us stronger!Strategic Partnering makes us stronger!some examples:some examples:
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 27/08.0927Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
AREAS OF R&D FOCUSAREAS OF R&D FOCUS
Psychiatry Cardiology Gastroenterology
Anxiety &Depression
Psychosis
Parkinsons*
Arrhythmia
Congestive Heart Failure
Hypertension
Obesity*
MotilityDisorders
IrritableBowel Syndrome
PancreaticEnzymes
Hormone Replacements
Women HRT*
Endometriosis*
Men HRT*
* External collaborations
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 28/08.0928Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
Hormone replacement therapies
17 %
Cardiology22 %
Psychiatry34 %
Gastroenterology27%
- in % of 2000 pharma R&D expenses : EUR 248 M(16% of pharma sales)
GROWTH THROUGH A SPECIALIZEDGROWTH THROUGH A SPECIALIZEDR&D PROGRAMR&D PROGRAM
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 29/08.0929Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
R & D SUMMARY - NUMBER OF PROJECTSR & D SUMMARY - NUMBER OF PROJECTS
Gastro-Enterology
CNS HRT Cardiology
Pre-Clinical= 7
3(IBS (2), Enzyme
Insufficiency)
2(Parkinson’s,Psychosis)
2 (Hypertension/CHF)
Phase I= 3
3 (Psychosis)
Phase II= 8
2(Motility
Disorders, enzyme insufficiency)
4 (Parkinson’s,
Psychosis, Pain/Spasticity, Depression)
2 (arrhythmia,
Hypertension/CHF)
Phase III= 8
2(IBS, EnzymeInsufficiency)
1(OCD/Social
anxiety disorders)
3 (female HRT,
male HRT)
2(Hypertension)
Total=26 7 10 3 6
PSYCHIATRYPSYCHIATRYportfolioportfolio
SLV308
RegistrationProof ofprinciple
Research
LUVOX® fluvoxamine CR
DEPRESSION EU/JPNOCD US/EU/JPNOCD/Social Anxiety Disorders
SCHIZOPHRENIA/PSYCHOSIS
Multiple Sclerosis Pain/Spasticity
PARKINSON’S
SCHIZOPHRENIA PSYCHOSIS
DU127090
SLV310SLV313
SLV314DEPRESSIONDU125530
preclinical SLV318, SLV319
THC (MARINOL®)
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 31/08.0931Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PSYCHIATRYPSYCHIATRY
LUVOX® DEPRESSION EU/JPNOCD US/EU/JPNOCD/Social Anxiety Disorders
ELAN manufacture SOLVAY trademark (to be decided) positive pivotal studies in both OCD +
Social Anxiety Disorders submission 2002 US, 12 months delay
after validation of manufacturing
launch date 2003 onwards
peak sales potential under 100 MEUR
fluvoxamine CR
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 32/08.0932Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PSYCHIATRYPSYCHIATRY
cannabinoid receptor agonist, tetrahydrocannabinol (THC)
launched in US for appetite stimulation in HIV/AIDS and nausea/vomiting caused by cancer chemotherapy
clinical studies ongoing in relief of pain and spasticity in multiple sclerosis sufferers
Multiple Sclerosis pain/SpasticityTHC (MARINOL®)
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 33/08.0933Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PSYCHIATRYPSYCHIATRY
DU127090 Solvay Pharmaceuticals partnership with Lundbeck for joint
developments and marketing Partial D2 antagonist with additional 5HT1A agonism Proof of principle as antipsychotic is completed
SLV310/313/314 different mechanism mixes D2, 5HT1A, SSRI
SLV319 : a preclinical potential candidate
SCHIZOPHRENIA/ PSYCHOSIS
DU127090SLV310SLV313SLV314
Launch date 2006Peak sales potential
above 250 MEUR
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 34/08.0934Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
The Lundbeck Example of partnershipThe Lundbeck Example of partnership
We created DU 127090 and described its anti-psychotic potential by animal work and phase I clinical studies, phase II is ongoing
DU127090 shows promising anti-psychotic activity Lundbeck has very relevant skills with CNS project
and product experience Solvay and Lundbeck share costs, programs &
marketing (Solvay : US+other countries, Lundbeck : Europe)
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 35/08.0935Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PSYCHIATRYPSYCHIATRY
SLV308 Partial D2 agonist plus 5HT1A agonism plus alpha-1 / alpha-2
agonism Parkinson’s first target + co-morbid depression Proof of principle studies on motor and mood disorders ongoing
Backup : SLV318 a preclinical potential candidate
PARKINSON’S SLV308
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 36/08.0936Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PSYCHIATRYPSYCHIATRY
Is a potent, full 5HT1A antagonist Atypical potential antidepressant Early clinical findings confirm antagonism in man with
opposite effects to buspirone, an agonist, on night time temperature and sleep
DEPRESSIONDU125530
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 37/08.0937Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
CARDIOLOGYCARDIOLOGYportfolioportfolio
CHF/ HYPERTENSION
ARRHYTHMIAS
TEVETEN®HCT
TEVETEN® EU / USACEON® US
PHYSIOTENS® EU HYPERTENSION
tedisamil IV-PO
preclinical SLV316, SLV320
moxonidine HCT
SLV306
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 38/08.0938Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
CARDIOLOGYCARDIOLOGY
HYPERTENSION
eprosartan plus hydrochlorotiazide (HCT) diuretic combinations
angiotensin II receptor antagonist to be marketed everywhere when registrations
and price agreementsachieved
“approvable letter” received from FDA
Launch date : 2001-2002Peak sales potential under
100 MEUR
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 39/08.0939Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
EFFICACY OF EPROSARTAN AND COMBINATIONS
eprosartan monotherapy works well for many hypertensive patients
eprosartan + HCT works well for some who need more than eprosartan alone
better response rate with eprosartan + HCT than with enalapril + HCT
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 40/08.0940Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
CARDIOLOGY
moxonidine plus HCT diuretic combination
to be marketed in EU when registrations and price agreements achieved
moxonidine HCT
Launch date : 2003Peak sales potential under
100 MEUR
RegistrationProof ofprinciple
Research
HYPERTENSION
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 41/08.0941Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
CARDIOLOGY
CHF/ HYPERTENSIONSLV306 Dual endopeptidase inhibitor NEP(1) and ECE(1)
hSEP is a novel ECE target (patent filed) selectively inhibited by SLV306 concept proven in both animals and man clinical proof of principle achieved for both
uses SLV306 is the front runner of this class development and marketing partnerships under
consideration(1) neutral endopeptidase (NEP) & endothelin converting enzyme (ECE)
Launch date : 2006Peak sales potential
above 250 MEUR
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 42/08.0942Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
CARDIOLOGY
ARRHYTHMIAS
potassium channel blocker intravenous use to convert atrial
fibrillation to sinus rhythm followed by oral use to maintain it
proof of principle achieved earliest launch 2004 intravenous and
2006 oral
tedisamil IV-PO
Launch date : 2004-2006Peak sales (IV+PO)
potential :100-250 MEUR
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 43/08.0943Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
GASTROENTEROLOGY portfolioportfolio
cilansetron US/EUDICITEL® EUCOLOFAC® EU IRRITABLE
BOWELSYNDROME
CREON® EU/USCREON® JPN
PANCREATICENZYMES
gastric lipase
MOTILITYDISORDERS
KC11458
preclinical SLV317, SLV321, enzymes
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 44/08.0944Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
GASTROENTEROLOGY
cilansetron US/EUDICITEL® EUCOLOFAC® EU IRRITABLE
BOWELSYNDROME
Cilansetron 5HT3 antagonist diarrhea-predominant IBS in men and women July 2001 decision to complete the phase III program Quintiles contract signed for clinical trials development and marketing commercial partnerships
now open for discussion
Launch date : 2004Peak sales potential
above 250 MEUR
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 45/08.0945Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
Start of the phase III program after constructive discussions with the US FDA
Agreement signed with QUINTILES TRANSNATIONAL access to state-of-the-art clinical trial execution with certain priority
claim on QUINTILES resources
ongoing talks with potential allianceand marketing partners
PROMISING and HIGH-POTENTIAL R&D PROJECTPROMISING and HIGH-POTENTIAL R&D PROJECTCILANSETRON FOR IBS IN PHASE IIICILANSETRON FOR IBS IN PHASE III
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 46/08.0946Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
KEY DATA KEY DATA FROM CILANSETRON IBS STUDIESFROM CILANSETRON IBS STUDIES
2 large studies with similar results, 471 and
435 patients
cilansetron phase II pivotal studies show clear
separation from placebo both in men and
women, fall 2000
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 47/08.0947Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
GASTROENTEROLOGY
CREON® EU/USCREON® JPN
PANCREATICENZYMES
CREON® JPN Launch date : 2003 Peak sales potential under 100 MEUR
gastric lipase non-animal-sourced range of enzymes sought “Molecular Pharming” technology expresses mammalian gastric-lipase in corn (MERISTEM) in-licensed for development, phase II ongoing
other non-animal-sourced enzyme products : preclinical
gastric lipase
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 48/08.0948Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
GASTROENTEROLOGY
MOTILITYDISORDERS
motilin agonist KC11458 is a non-peptide macrolide intended to be of use in the delayed gastric emptying found in some diabetic
gastroparesis patients and functional dyspepsias clinical studies show dose dependent effects in man confirming faster gastric
emptying phase II ongoing
KC11458
RegistrationProof ofprinciple
Research
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 49/08.0949Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
HORMONE REPLACEMENTS portfolioportfolio
ESTROGEL® USPRESOMEN® EUFEMOSTON® EU
WOMEN’S HRT
ANDROGEL® US MEN’S HRT
ESTRATEST® US
E+P GEL US/EU
RegistrationProof ofprinciple
Research
Evaluation : testosterone for female use
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 50/08.0950Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
HORMONE REPLACEMENTS
ESTROGEL® US
Launch date : 2003Peak sales potential under 100 MEUR
RegistrationProof ofprinciple
Research
New Drug Application submitted to FDA 1999
WOMEN’S HRT
HORMONE REPLACEMENTS
WOMEN’S HRTE+P GEL US/EU
Estradiol + NETA (progestogen) gel Solvay has obtained licenses for
US/Canada and Europe Clinical studies necessary to start
full-development have been completed
Phase III program to be started in Q1 2002
RegistrationProof ofprinciple
Research
Launch date : 2005Peak sales potential
under 100 MEUR
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 52/08.0952Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
INFLUENZA VACCINES
INFLUVAC ® our current product was manufactured by Fort Dodge/AHP. We bought the factory mid 2001 in order to secure and expand manufacturing
WEST PHARMACEUTICALS intranasal formulation technology license obtained mid 2001 for use with our INFLUVAC ® launch expected 2005
MDCK process approved by Dutch authorities mid 2001, launch dates depend on future partnerships
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 53/08.0953Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
2001 2003 2004 2005 2006
Teveten + HCT, Europe and U.S.< 100 MEUR
Moxonidine + HCT (Europe)<100 MEUR
Luvox CR<100MEUR
Creon (Japan)<100MEUR
Estrogel US<100MEUR
Cilansetron,Europe and U.S.
> 250MEUR
Tedisamil IV
CombigelE + P-gel
<100MEUR
Influvac-Intranasal<100MEUR
SLV 306>250MEUR
DU 127090>250MEUR
Tedisamil PO100-250MEUR
VALUATION OF R & D PORTFOLIOVALUATION OF R & D PORTFOLIOPeak sales Peak sales POTENTIAL POTENTIAL (3 years or more after launch)(3 years or more after launch)
This represents an all-success scenario, individual projects are subject to industry standard probabilities of success for their respective stage of development
LAUNCHLAUNCHDATESDATES
© 2001, SOLVAY S.A.SOLVAY PPT-6684ALR 54/08.0954Analysts and Investors Meeting (Sept. 14, 2001)Analysts and Investors Meeting (Sept. 14, 2001)
PHARMACEUTICALS R&D A Discovery with Proven Output AbilityA Discovery with Proven Output Ability
and a continuing search for external technologies and alliances
A Development with Proven Abilities to Proof Of PrincipleA Development with Proven Abilities to Proof Of Principle recent examples being cilansetron and SLV306
An Ability to Complete Full DevelopmentsAn Ability to Complete Full Developments recent examples being ESTROGEL® and fluvoxamine CR
And A Willingness to Work with Skilled PartnersAnd A Willingness to Work with Skilled Partners Lundbeck on DU127090 and Discussion ongoing for cilansetron, SLV306 and others
and … Innovation
Visit our Internet sitespecifically designed for Investors
www.solvay-investors.com
and become member of our Shareholders’ Club